GlassScriptPhysician profile
Laurie A Barkway
NPI 1003870031
$1,799.18
in general payments reported to CMS, 2019-2025
27 companies · $540 in 2025
The $540 reported for 2025 was more than what 75% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $274 · 2020: $55.60 · 2021: $50.34 · 2022: $25.00 · 2023: $234 · 2024: $620 · 2025: $540.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,394.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,393.86 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $295.08 | 2023-2025 | Vraylar |
| Pfizer INC. | $279.57 | 2019-2025 | |
| Novo Nordisk INC | $274.68 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Glaxosmithkline, LLC. | $108.14 | 2019-2023 | Trelegy Ellipta |
| Dexcom, INC. | $101.60 | 2024-2025 | Dexcom G6 Transmitter |
| Otsuka America Pharmaceutical, INC. | $76.79 | 2023-2025 | Rexulti |
| Lilly USA, LLC | $75.45 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Boston Scientific Corporation | $64.68 | 2025 | Wavewriter Alpha Prime 16 |
| Amgen INC. | $56.56 | 2019-2025 | Otezla, Repatha |
| Merck Sharp & Dohme LLC | $53.54 | 2019-2024 | Dificid |
| Ironshore Pharmaceuticals INC. | $45.58 | 2019-2024 | |
| Janssen Pharmaceuticals, INC | $42.51 | 2020-2021 | |
| Novartis Pharmaceuticals Corporation | $34.17 | 2019 | |
| Cranial Technologies, INC | $33.40 | 2024 | Doc Band |
| Grifols USA, LLC | $29.46 | 2024 | Prolastin-C Liquid |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exact Sciences Corporation | $27.39 | 2023-2025 | Cologuard Collection Kit |
| Allergan, INC. | $26.41 | 2019 | |
| Vertical Pharmaceuticals, LLC | $26.08 | 2019-2025 | Relexxii |
| Sanofi-Aventis U.S. LLC | $24.77 | 2019 | |
| Axsome Therapeutics, INC. | $23.54 | 2025 | Auvelity |
| Teva Pharmaceuticals USA, INC. | $20.11 | 2021 | |
| Shire North American Group INC | $17.07 | 2019 | |
| Astellas Pharma US INC | $15.06 | 2024 | Veozah |
| Takeda Pharmaceuticals U.S.A., INC. | $12.87 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $12.72 | 2023 | Livalo, Seglentis |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $11.08 | 2020 | |
| Astrazeneca Pharmaceuticals LP | $10.87 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Laurie Barkway listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.